Letter: Thiopurine blood monitoring for patients with inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 6, 2012, Pages 742-

  El Matary, W ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE;

ALGORITHM; ANXIETY; BLOOD CELL COUNT; BLOOD EXAMINATION; BONE MARROW TOXICITY; DRUG MONITORING; ENTERITIS; EVIDENCE BASED PRACTICE; GENERAL PRACTITIONER; HUMAN; LETTER; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION;

AZATHIOPRINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; THIOGUANINE;

EID: 84857346029     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.04995.x     Document Type: Letter

References (3)

1. Chouchana L, Narjoz C, Beaune P, Loriot MA, Roblin X,. Review article: the benefits of phamacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 15-36.
2. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE,. Bone marrow toxicity caused by azathiopurine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 1081-5.
3. French H, Dalzell AM, Srinivasan R, El-Matary W,. Relapse rate following azathioprine withdrawal in maintaining remission for Crohn's disease: a meta-analysis. Dig Dis Sci 2011; 56: 1929-36.